>
产品中心 >
Small_molecule >
Medchemexpress/Daclatasvir(同义词:BMS-790052;EBP 883)/HY-10466/200mg
CustomerValidation
- •EMBORep.2016Jul;17(7):1013-28.
- •PLoSPathog.2017May11;13(5):e1006374.
- •IntJRADIatOncolBiolPhys.2016Nov15;96(4):867-876.
- •JVirol.2014May;88(10):5578-94.
- •FrontPharmacol.2016Dec21;7:490.
- •IntJAntimicrobAgents.2015Oct;46(4):381-8.
- •AntimicrobAgentsChemother.2015May;59(5):2496-507.
- •AntimicrobAgentsChemother.2014Aug;58(8):4555-64.
- •AntimicrobAgentsChemother.2014Jun;58(6):3327-34.
- •AntimicrobAgentsChemother.2013Mar;57(3):1180-91.
- •AntiviralRes.2017Oct;146:191-200.
- •AntiviralRes.2017Oct23;148:5-14.
- •PLoSOne.2016Jul21;11(7):e0159511.
- •PLoSOne.2016Apr22;11(4):e0152036.
- •PLoSOne.2015Aug11;10(8):e0134707.
- •VirusRes.2017Mar18;235:37-48.
- •TransplInfectDis.2017Nov7.
- •HepatolCommun.2017;1(6).
- •HepatolCommun.June6,2017.
- •OpenVirolJ.2014Mar7;8:1-8.
Description | DaclatasvirisapotentHCVNS5Aproteininhibitor,withmeanEC50valuesof50and9pMagainstgenotype1aand1breplicons,respectively. |
---|---|
IC50&Target | EC50:9±4pM(HCVreplicongenotype1b,inCon1cells),50±13pM(HCVreplicongenotype1a,inH77cells)[1] |
InVitro | Daclatasvir(BMS-790052)isasmallmoleculeinhibitoroftheHCVNS5Aproteinthatexhibitspicomolarhalf-maximumeffectiveconcentrations(EC50)towardsrepliconsexpressingabroadrangeofHCVgenotypesandtheJFH-1genotype2ainfectiousvirusincellculture.DaclatasvirisapotentinhibitoroftheJFH-1genotype2ainfectiousvirusthatreplicatesincellculture(EC50=28pM),anassayconsideredtobeamoreBIOLOGicallyrelevantinvitrocellculturesystem.Inaddition,DaclatasvirdisplayssimilarpotencyinHuh-7,HeLaandHEK293Tcells,demonstratingthatthefunction(s)ofNS5AinhibitedbyDaclatasviris(are)highlyconservedindifferentcellularenvironments[1]. |
InVivo | Inarandomized,double-blind,placebo-controlled,singleascending-dosestudy,Daclatasvir(BMS-790052)isadmiNISTeredatsixdoselevelstohealthy,non-HCV-infectedsubjectsoverarangeof1to200mgasanoralsolution.Daclatasvirissafeandwelltoleratedupto200mgwithnoclinicallyrelevantadverseeffects.Afteroraladministration,Daclatasvirisreadilyabsorbed,withdose-proportionalexposuresoverthestudieddoserange,andallsubjectshavedrugconcentrationsgreaterthantheprotein-binding-adjustedEC90forgenotypes1aand1b,asmeasuredintherepliconassay,atandbeyond24hpost-dose.(Theproteinbinding-adjustedEC90figuresarederivedfromananalysisoftheeffectoftheadditionofhumanserumonantiviralactivityinreplicons.Inthepresenceof40%humanserum,theEC90forDaclatasviris383pM(0.28ng/mL)forthegenotype1arepliconand49pM(0.04ng/mL)forthegenotyope1breplicon)[1].MiceineachgroupthatdevelopedpersistentHCVinfectionaredividedintotwotreatmentgroups.Onegroupreceive4weeksofAsunaprevir/Daclatasvirtreatmentandtheothergroupreceived4weeksofLedipasvir/GS-558093treatment.Asunaprevir/DaclatasvirtherapyandLedipasvir/GS-558093therapyrapidlydeceaseserumHCVRNAlevelstobelowthesensitivity,andtheyarenotdetectedaftercompletionofthetherapyexceptfortwomiceintheLedipasvir/GS-558093group[2]. |
ClinicalTrial | ViewMoreCollapse |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellAssay [1] | Daclatasvir(BMS-790052)isdissolvedinDMSOandstored,andthendilutedwithappropriatemediabeforeuse[1]. HCVgenotype1aand1brepliconcellsaremaintainedinmediacontainingDaclatasvirataconcentrationof5-to20-foldaboveEC50and0.5mg/mLG418.RepliconcellssimilarlytreatedwithDMSOaremaintainedascontrols.Afterapproximately4-5weekswhencellgrowthissimilartoDMSO-treatedcontrolcells,selectedcellsareexpandedforresistancetestingandanalysisbyPCRwithreversetranscription[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
AnimalAdministration [2] | Daclatasvir(BMS-790052)isdissolvedinDMSOanddilutedwithsaline[2]. Mice[2] | ||||||||||||||||
References |
|
MolecularWeight | 738.88 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₄₀H₅₀N₈O₆ | ||||||||||||
CASNo. | 1009119-64-5 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | DMSO:≥40mg/mL *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> Purity:99.31% 品牌介绍
托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH,5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50~89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者,应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射,并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似,均可达81%~100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用,可加快代谢,故快代谢型者需增加剂量,慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶,熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride):C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应,可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品
联络我们
|